OSMI-1: A Precise O-GlcNAc Transferase Inhibitor for Research

Executive Summary: OSMI-1 (B7923) is a cell-permeable, small molecule O-GlcNAc transferase (OGT) inhibitor with an IC₅₀ of 2.7 μM, validated in vitro and in vivo (APExBIO). OSMI-1 reduces O-GlcNAcylation of cellular proteins, exemplified by mass shift in Nup62. In CHO cells, 50 μM OSMI-1 reduces viability by approximately 50% after 24 hours, indicating potent cellular activity. Acute toxicity in zebrafish yields LC₅₀ values of 56 μM (12 h) and 45 μM (24 h). OSMI-1 is supplied at >98% purity, soluble at ≥50.6 mg/mL in DMSO, and should be stored at −20°C (product specification).

Biological Rationale

O-GlcNAcylation is a dynamic post-translational modification regulating protein function, stability, and localization. OGT catalyzes transfer of O-GlcNAc from UDP-GlcNAc to serine/threonine residues on target proteins. Aberrant O-GlcNAcylation is implicated in diverse cellular processes, including signaling, metabolism, and stress response. In placental biology, O-GlcNAc modification of HUWE1 orchestrates transferrin receptor 1 (TfR1) ubiquitination, limiting iron uptake and ferroptosis in trophoblasts—a mechanism central to the pathology of preeclampsia (Zhang et al., 2026). Targeted inhibition of OGT via small molecules like OSMI-1 enables precise interrogation of O-GlcNAc pathway function in cellular and animal models of disease.

Mechanism of Action of OSMI-1

OSMI-1 is a competitive, cell-permeable inhibitor targeting the catalytic domain of OGT. By blocking the transfer of O-GlcNAc to substrate proteins, OSMI-1 decreases global O-GlcNAcylation levels in cells. This reduction is directly measurable by mass spectrometry as a loss of O-GlcNAc residues on proteins such as nucleoporin62 (Nup62) (product details). OSMI-1 also results in secondary decreases in O-GlcNAcase (OGA) protein levels, a feedback effect observed in treated cells. The compound is effective at concentrations as low as 2.7 μM (IC₅₀), with cytotoxic effects evident at higher doses and longer exposures. Its high solubility in DMSO (>50 mg/mL) enables consistent delivery in cell-based assays.

Evidence & Benchmarks

• OSMI-1 inhibits OGT with an IC₅₀ of 2.7 μM in biochemical assays (product specification).
• Global protein O-GlcNAcylation is reduced upon OSMI-1 treatment, as shown by mass-shift of Nup62 in mass spectrometry analyses (APExBIO).
• In CHO cell viability assays, 50 μM OSMI-1 lowers cell survival by ~50% after 24 h (product page).
• Acute in vivo zebrafish toxicity: LC₅₀ is 56 μM (12 h) and 45 μM (24 h) (APExBIO).
• Elevated O-GlcNAcylation in trophoblasts stabilizes HUWE1, driving TfR1 degradation, limiting iron uptake, and inhibiting ferroptosis (Zhang et al., 2026).

This article updates and extends prior reviews such as "OSMI-1: A Precise O-GlcNAc Transferase Inhibitor for Ferroptosis Research" by providing explicit in vivo toxicity metrics and clarifying OSMI-1’s role in placental biology models; this level of detail is not present in previous summaries focused only on in vitro applications.

Applications, Limits & Misconceptions

OSMI-1 is a principal tool for dissecting O-GlcNAcylation in cellular signaling, mitochondrial homeostasis, and ferroptosis research. It has been widely adopted for studies of protein O-GlcNAc modification, especially in the context of placental pathology and preeclampsia (see O-GlcNAcylation Regulates Ferroptosis and Trophoblast Syncytialization). By inhibiting OGT activity, OSMI-1 enables controlled reduction of O-GlcNAcylation, facilitating mechanistic investigation of downstream pathways. For example, OSMI-1 has been used to demonstrate that loss of O-GlcNAcylation exacerbates ferroptosis and impairs trophoblast syncytialization, providing a model for PE pathogenesis (O-GlcNAcylation Regulates Ferroptosis in Preeclampsia via HUWE1-TfR1 Axis), thus extending the mechanistic framework beyond what is addressed in single-pathway reviews.

Common Pitfalls or Misconceptions

• Non-selectivity at high concentrations: Cytotoxicity is evident at ≥50 μM; off-target effects may confound interpretation in viability assays (product data).
• Ineffective in ethanol/water: OSMI-1 is insoluble in water and ethanol, leading to precipitation and unreliable dosing if not used in DMSO (product specification).
• Long-term solution storage: Solutions degrade over time; prepare fresh aliquots for each experiment (APExBIO).
• Species limitations: Zebrafish LC₅₀ values may not extrapolate to mammalian safety profiles (product info).
• Does not directly inhibit OGA: OSMI-1 reduces OGA levels indirectly; it is not an OGA inhibitor (product specification).

Workflow Integration & Parameters

• Dissolution: Dissolve OSMI-1 at ≥50.6 mg/mL in DMSO for stock solutions; avoid water or ethanol as solvents.
• Working concentration: Typical cell-based assays use 1–50 μM; significant OGT inhibition and O-GlcNAcylation reduction observed at 10–20 μM.
• Viability monitoring: At ≥50 μM, expect ~50% reduction in CHO cell viability at 24 h; titrate accordingly for cytotoxicity-sensitive assays.
• In vivo zebrafish: Use ≤45 μM to minimize acute toxicity; monitor for phenotypic endpoints within 24 h.
• Storage: Store powder at −20°C; use prepared solutions immediately and avoid repeated freeze-thaw cycles.

Conclusion & Outlook

OSMI-1, produced and quality-controlled by APExBIO, is a benchmark O-GlcNAc transferase inhibitor for mechanistic studies of O-GlcNAcylation, ferroptosis, and protein homeostasis. Its well-defined potency, solubility, and toxicity profiles make it an essential reagent for dissecting the roles of OGT in health and disease. As recent research underscores the therapeutic potential of modulating O-GlcNAcylation in placental disorders, OSMI-1’s validated performance supports robust, reproducible experimentation. Future work will further clarify its applications in disease modeling and therapeutic target validation, particularly in preeclampsia and related pathologies (Zhang et al., 2026).